Schizophrenia News and Research

Latest Schizophrenia News and Research

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

AstraZeneca and Targacept, Inc. today announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD).

3 Dec 2009

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

2 Dec 2009

Integrated eating disorders center to be launched shortly

NewYork-Presbyterian Hospital, Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, in affiliation with the New York State Psychiatric Institute, announced the creation of an integrated eating disorders center. Opening today is a key clinical component of this new center -- The Outlook at NewYork-Presbyterian Hospital/Westchester Division in White Plains.

2 Dec 2009

Galenea and Otsuka Pharmaceutical extend their research and development collaboration

Galenea Corp. and Otsuka Pharmaceutical Co., Ltd. announced today the further extension of their research and development collaboration through 2011. This latest extension increases the collaboration term to seven years and brings the total committed funding to approximately $90 million.

2 Dec 2009

MRI pioneer honored with MRC Millennium Medal

Sir Peter Mansfield, The University of Nottingham's Nobel Laureate for Physiology and Medicine, is to be recognised, once again, for his part in one of the most important breakthroughs in medical science.

2 Dec 2009

Antipsychotic medications increase the levels of inflammation markers, find researchers

Overall, antipsychotic medications are reasonably effective, and fairly well tolerated treatments for mood and psychotic disorders. However, treatment with a number of antipsychotic medications is associated with weight gain, and for some, hyperglycemia and hyperlipidemia.

2 Dec 2009

Pharmacy-based intervention improves antipsychotic adherence among patients with mental illnesses

Health systems should consider pharmacy-based interventions when involving patients who have poor follow-through taking medication.

24 Nov 2009

Groundbreaking discovery provides fundamental insights into neurological disorders

Dr. Jeremy Schmahmann, Professor of Neurology at Harvard Medical School and neurologist at the Massachusetts General Hospital in Boston, on Thursday, November 19, presented his laboratory's research on the new field of study called "Connectivity" at the launch of the MINDlink Foundation.

21 Nov 2009

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.

21 Nov 2009

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

20 Nov 2009

Brain uses a mechanism to filter out distracting thoughts to focus on single information

The human brain is bombarded with all kinds of information, from the memory of last night's delicious dinner to the instructions from your boss at your morning meeting. But how do you "tune in" to just one thought or idea and ignore all the rest of what is going on around you, until it comes time to think of something else?

19 Nov 2009

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.

18 Nov 2009

Review of the results of Phase 2b clinical trial on PASCAL announced

ARYx Therapeutics, Inc., a biopharmaceutical company, announced that a review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of atrial fibrillation, budiodarone, was presented today at the American Heart Association meeting in Orlando, Florida.

18 Nov 2009

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

17 Nov 2009

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).

17 Nov 2009

New research provides valuable international profile of mental health disorder

An international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range of patients and healthcare systems in 37 different countries.

17 Nov 2009

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared with a net loss applicable to common stock of $3,148,000, or $0.07 per share for the corresponding prior year period.

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Study finds striking similarities in people with schizophrenia across 37 different countries

16 Nov 2009

Schizophrenia News and Research

Latest Schizophrenia News and Research

AstraZeneca and Targacept enter into agreement to develop and commercialize TC-5214

Generic erosion to decrease branded atypical antipsychotics schizophrenia drug market to $5.2B

Integrated eating disorders center to be launched shortly

Galenea and Otsuka Pharmaceutical extend their research and development collaboration

MRI pioneer honored with MRC Millennium Medal

Antipsychotic medications increase the levels of inflammation markers, find researchers

Pharmacy-based intervention improves antipsychotic adherence among patients with mental illnesses

Groundbreaking discovery provides fundamental insights into neurological disorders

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

FDA approves sNDA for pediatric autism drug ABILIFY

Brain uses a mechanism to filter out distracting thoughts to focus on single information

BIMR wins a GO grant from the National Institute of Mental Health

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Review of the results of Phase 2b clinical trial on PASCAL announced

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

New research provides valuable international profile of mental health disorder

Cortex Pharmaceuticals reports a net loss of $0.06 per share for the quarter ended September 30, 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Study finds striking similarities in people with schizophrenia across 37 different countries

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Schizophrenia News and Research

Latest Schizophrenia News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in